Table 6.

Multivariate analysis of DFS and OS in HER2-overexpressed patients

Factors	DFS HR				OS HR
	Average	Lower	Upper	P-value	Average	Lower	Upper	P-value
Age	1.02	0.95	1.10	0.602	1.04	0.96	1.13	0.337
T stage	3.72	1.08	12.82	0.037	3.47	1.04	11.50	0.042
N stage	8.15	1.05	63.47	0.045	4.50	0.47	43.01	0.191
ER	1.15	0.20	6.83	0.876	0.85	0.13	5.53	0.867
TAM	0.23	0.03	1.72	0.151	0.15	0.02	1.64	0.121
Other endoa	1.27	0.20	8.01	0.802	0.78	0.12	5.25	0.800
Chemotherapy	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GPER1	7.57	1.03	55.58	0.047	6.63	0.93	47.02	0.059

Note:

^aOther endo: other endocrine therapy except for TAM.

Abbreviations: DFS, disease-free survival; ER, estrogen receptor; GPER1, G protein-coupled estrogen receptor 1; HR, hazard ratio; N/A, not available; OS, overall survival; TAM, tamoxifen treatment.